Eli Lilly and Company: Head and Neck Neoplasms trials
The registry lists 14 Head and Neck Neoplasms studies with Eli Lilly and Company as lead sponsor. 1 are open to participants now and 11 have results posted.
Phase 1 5Phase 2 11Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2
- A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) TumorsActive, not recruitingNCT03899792Phase 1/2Results posted
- A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)Active, not recruitingNCT03157128Phase 1/2Results posted
- A Study of AK-01 (LY3295668) in Solid TumorsCompletedNCT03092934Phase 1/2Results posted
- Study in Advanced Solid TumorsCompletedNCT01099358Phase 2Results posted
- A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck CancerCompletedNCT01087970Phase 2Results posted
- A Study in Head and Neck CancerCompletedNCT01081041Phase 2Results posted
- A Study in Advanced Solid TumorsCompletedNCT01063075Phase 2Results posted
- A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and NeckCompletedNCT01059643Phase 2Results posted
- A Study for Patients With Recurrent or Metastatic Squamous Cell Head and Neck CancerCompletedNCT01057589Phase 2Results posted
- Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and NeckCompletedNCT00617734Phase 2Results posted
- A Study for Patients With Head and Neck CancerCompletedNCT00415194Phase 3Results posted
- A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck CancerCompletedNCT02555644Phase 1
- Head and Neck Cancer Registry (LORHAN)CompletedNCT01080313